Project lead: SARS-CoV-2. Designed, constructed and validated vaccines for multiple indications, including several which have progressed into the clinic for SARS-CoV-2 and norovirus indications. Responsible for design, construction, and validation of vaccines against emerging SARS-CoV-2 Variants of Concern/Variants of interest. Spearheaded incremental technology improvement for Vaxart's oral-tablet modular vaccination platform.

Investor outreach for private financing; market research and financial forecasting/modeling for existing and proposed vaccine programs; search and evaluation; in-licensing of novel targets for Vaxart's oral vaccine platform; partnering negotiations for Vaxart programs; M&A: part of senior management team that closed $30M+ merger with Aviragen Therapeutics in 2018 (NASDAQ: VXRT); ran full BD process for two small-molecule antiviral programs brought in through merger with AVIR; supported negotiation of R&D collaboration deal with Janssen in 2019 with option to expand following data analysis in 2020; internal development of COVID-19 vaccine program.

Supervisor, Molecular Virology Department (2015-2016):Project Lead: Chikungunya Vaccines - 100% protection in murine challenge model (Vaccine, 2019 May 27;37(24):3146-3150)Project Lead: Zika VaccinesSenior Research Associate, Molecular Virology (2013-2015):Design, construction and validation of vaccines to support Vaxart's proprietary recombinant oral vaccine delivery platform based on replication-deficient adenovirus 5 with novel adjuvant. My norovirus vaccine construct is currently in two Phase 2 clinical trials with read-outs scheduled for Q3 2023. Consultant, Process Development (2012-2013)Optimization of viral production processes to produce Vaxart's recombinant vaccines

Co-founder of a venture developing a web-based collaboration platform. Responsible for market research, consumer behavior evaluation, market planning, user interactions, and business development activities. MetaNotes' alpha release won a Web Award for Most Innovative Technology at SXSW Interactive in March 2010.

Attended on full scholarship (Starling Life Sciences Fellow). Graduated with Honors (top 10%). Activities: President of the Healthcare Industry Club, Vice President of the Entrepreneurship Club, and acting member of the Venture Capital/Private Equity Club. Helped organize the Venture Capital Investment Competition, an internationally attended competition placing competitors in the role of VCs evaluating business opportunities presented by real entrepreneurs and participated in by every business school in the top 30.Received international exposure through an exchange term in Hong Kong, as well as a school-sponsored trip to India during which we visited companies throughout the country to learn about Indian business practices.

MBA internship within the Business Development group to explore partnering opportunities for Liquidia technology. Performed extensive primary and secondary research to support market assessment analyses for Liquidia technology within life sciences. Drafted two sections of the Liquidia business plan which clearly articulated the opportunities and risks of operating within the biotech/pharma spaces. Liquidia closed a $16M Series B round of financing soon after this work was completed.

Collaborated with research department team leaders to identify, develop, and provide needed reagents and molecular cloning expertise in support of preclinical pipeline research.

Co-designed and led a successful genetic screen to identify potential therapeutic drug targets for colon cancer treatment, resulting in significant addition to the Exelixis IP portfolio (16 patent applications). Proposed and spearheaded successful development of a novel yeast-based technique for mechanism-of-action analysis of therapeutic oncology compounds.

Aided in successful design of a novel gene therapy delivery system based upon manipulation of adenovirus within yeast (Hum Gene Ther. 2003 Mar 1;14:329-39).